Related Experiment Video
Updated: Oct 2, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
The Blood Pressure Lowering Treatment Trialists' Collaboration: methodological clarifications of recent reports
Milad Nazarzadeh1,2, Dexter Canoy1,2,3, Zeinab Bidel1,2
1Deep Medicine, Oxford Martin School.
Insights
Pooled data from over 360,000 individuals in 52 trials confirm blood pressure lowering treatments reduce cardiovascular disease risk. This analysis clarifies uncertainties regarding treatment efficacy and safety in diverse patient groups.
Area of Science:
- Cardiology
- Clinical Trials
- Epidemiology
Background:
- Elevated blood pressure is a known risk factor for cardiovascular diseases (CVDs).
- Limited randomized evidence exists on how blood pressure levels at treatment initiation impact CVD risk reduction.
- The influence of patient characteristics (e.g., prior disease, age, sex) on treatment effectiveness is debated.
Purpose of the Study:
- To clarify uncertainties regarding the stratified efficacy and safety of antihypertensive therapy.
- To address gaps in knowledge concerning blood pressure management and cardiovascular outcomes.
- To clarify methods used in pooled analyses of blood pressure-lowering treatment trials.
Main Methods:
- Utilized individual-level participant data from 52 randomized clinical trials.
- Included over 360,000 participants in the analysis.
- Leveraged the Blood Pressure Lowering Treatment Trialists' Collaboration dataset, the largest of its kind.
Main Results:
- Pooled analyses have successfully addressed long-standing knowledge gaps in antihypertensive therapy.
- Demonstrated the power of large-scale data aggregation for clinical insights.
- Clarified methodological approaches for interpreting trial data.
Conclusions:
- The Blood Pressure Lowering Treatment Trialists' Collaboration dataset is a powerful resource for understanding antihypertensive therapy.
- Pooled analyses provide critical evidence for optimizing cardiovascular disease prevention strategies.
- Accurate interpretation of trial data is essential for advancing clinical practice.
Abstract:
Epidemiological evidence has consistently shown that people with higher systolic or diastolic blood pressure are at greater risk of cardiovascular diseases. However, there has been limited randomized evidence to determine the role of blood pressure level at treatment initiation in the reduction of cardiovascular diseases risk. The extent to which other characteristics of individuals, such as prior disease history, age or sex, should be taken into account has also been controversial. Furthermore, effects on less commonly reported efficacy and safety outcomes remain underexplored. The Blood Pressure Lowering Treatment Trialists' Collaboration has collected individual-level participant data from 52 randomized clinical trials, with more than 360 000 participants, and is now the largest source of individual-level data from randomized clinical trials of blood pressure-lowering treatment. This resource provides an unprecedented opportunity to address major areas of uncertainty relating to stratified efficacy and safety of antihypertensive therapy. Recent reports have demonstrated the power of pooled analyses of the Blood Pressure Lowering Treatment Trialists' Collaboration dataset in filling long-standing gaps in our knowledge. However, there have been some misconceptions regarding the methods underpinning the recent reports, which we clarify in this article.
More Related Videos
Related Concept Videos
Errors occurring during blood pressure monitoring
Several factors...
Blind Procedures
Hypertension III: Clinical Manifestations and Diagnostic Studies
Blinding
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Pre-Procedural Guidelines for Assessing Blood Pressure

